Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Binimetinib + Encorafenib for Melanoma
Recruiting1 awardPhase 2
Houston, Texas
This trial studies how well binimetinib and encorafenib work in patients with melanoma that has spread to the brain. These medications may help stop cancer growth by blocking important enzymes. The trial focuses on patients with a specific mutation (BRAFV600) whose cancer has spread to critical areas. Encorafenib and binimetinib are FDA-approved for treating metastatic melanoma with BRAFV600 mutations.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service